Company Encyclopedia
View More
name
Salarius Pharmaceuticals
SLRX.US
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology.
1.946 T
SLRX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Salarius Pharmaceuticals To Collaborate With Texas Biomedical Research Institute On Avian Flu Study

    Dec 1 (Reuters) - Salarius Pharmaceuticals Inc:* SALARIUS PHARMACEUTICALS TO COLLABORATE WITH TEXAS BIOMEDICAL RESEARCH INSTITUTE ON AVIAN FLU STUDY Source text: Further company coverage:

    Reuters·
    US
    SLRX
    +1.28%
    Reuters·
    US
    SLRX
    +1.28%

    Dir Hanish Buys 5,000 ($3.7K) Of Salarius Pharmaceuticals Inc [SLRX]

    Hanish Arnold C Director of Salarius Pharmaceuticals Inc [SLRX] filed a Form 4 on November 24, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/20/25TransactionPurchaseShares5,000Price$0.75Value$3,741Ending Holdings: 5,027 (12 - Direct, 5,015 - Indirect) For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    SLRX
    +1.28%
    Reuters·
    US
    SLRX
    +1.28%

    Salarius Pharmaceuticals Director Arnold C. Hanish Reports Acquisition of Common Shares

    Arnold C. Hanish, Director of Salarius Pharmaceuticals, reported acquiring common shares of the company. The original filing is available via EDGAR, published by Salarius Pharmaceuticals on November 24, 2025. This AI-generated news brief is for informational purposes only and not financial advice.

    Reuters·
    US
    SLRX
    +1.28%
    Reuters·
    US
    SLRX
    +1.28%

    Salarius Pharmaceuticals Files Initial Beneficial Ownership Statement for Chief Scientific Officer Barbara Louise Hibner

    Salarius Pharmaceuticals Inc. has filed an initial statement of beneficial ownership for its Chief Scientific Officer, Barbara Louise Hibner. The filing is accessible via EDGAR, the SEC's system. This news brief was generated by Public Technologies using AI and is for informational purposes only, not financial advice.

    Reuters·
    US
    SLRX
    +1.28%
    Reuters·
    US
    SLRX
    +1.28%

    Salarius Pharmaceuticals Files Initial Beneficial Ownership Statement for Chief Business Officer Peter Klaus Marschel

    Salarius Pharmaceuticals Inc. has filed a statement of beneficial ownership with the SEC, naming Peter Klaus Marschel as the beneficial owner and Chief Business Officer. The filing is accessible via EDGAR, the SEC's system. This news brief was generated by Public Technologies using AI and is not financial advice.

    Reuters·
    US
    SLRX
    +1.28%
    Reuters·
    US
    SLRX
    +1.28%
    © 2025 Longbridge｜Disclaimer